While the biopharma industry and pharmacy benefit managers (PBMs) have spent the last four years consumed by the capacity, contracting, and formulary economics of glucagon-like peptide-1 (GLP-1) receptor agonists, a late-stage readout on August 18, 2026, opened the commercial ledger for the class's exact pharmacological opposite: the first GLP-1 receptor antagonist.
Amylyx Pharmaceuticals announced positive topline results from the pivotal Phase 3 LUCIDITY trial (NCT06747468) evaluating avexitide (90 mg once-daily subcutaneous injection) in 78 participants suffering from post-bariatric hypoglycemia (PBH) following Roux-en-Y gastric bypass (RYGB).
The trial met its FDA-agreed primary endpoint with exceptional statistical power: avexitide achieved a 55% reduction in the composite rate of Level 2 and Level 3 hypoglycemic events versus placebo through 16 weeks of double-blind therapy (p = 0.000003). Crucially for a metabolic patient population that underwent bariatric surgery to reverse morbid obesity, avexitide demonstrated zero difference in body weight compared to placebo and reported no treatment-related serious adverse events (SAEs).
With an FDA New Drug Application (NDA) planned for submission by the end of 2026 and an active U.S. Expanded Access Program (EAP) already open, avexitide is positioned to become the first FDA-approved treatment for a severe metabolic complication affecting an estimated 160,000 Americans.
For specialty pharmacy directors, commercial medical directors, and Medicaid P&T committees currently paying for an uncoordinated, poorly tolerated patchwork of off-label therapies, avexitide's readout demands immediate benefit-design preparation.
What did the Phase 3 LUCIDITY trial actually show?
The Phase 3 LUCIDITY trial was a 78-participant, multicenter, randomized, double-blind, placebo-controlled pivotal study conducted across 21 clinical sites in the United States. Participants were randomized 3:2 to receive either 90 mg of avexitide administered as a once-daily subcutaneous injection or matching placebo for a 16-week double-blind treatment period, followed by an ongoing 32-week open-label extension (OLE).
┌─────────────────────────────────────────────────────────────┐
│ PHASE 3 LUCIDITY TRIAL DESIGN (NCT06747468) │
│ 78 Adults with Severe PBH Following RYGB │
└──────────────────────────────┬──────────────────────────────┘
│ 3:2 Randomization
┌──────────────────────┴──────────────────────┐
▼ ▼
┌──────────────────────────────┐ ┌──────────────────────────────┐
│ Avexitide 90 mg │ │ Matching Placebo │
│ Once-Daily SubQ │ │ Once-Daily SubQ │
└──────────────┬───────────────┘ └──────────────┬───────────────┘
│ │
└──────────────────────┬──────────────────────┘
│ 16-Week Double-Blind Period
▼
┌─────────────────────────────────────────────────────────────┐
│ PRIMARY ENDPOINT RESULT │
│ 55% Reduction in Composite Level 2/3 Hypoglycemia (p=3e-6) │
├─────────────────────────────────────────────────────────────┤
│ • SMBG-measured Level 2 events: Statistically significant │
│ • CGM-measured Level 2 events: Statistically significant │
│ • Adjudicated Level 3 events: Statistically significant │
│ • Body Weight: No difference vs placebo (weight neutral) │
│ • Safety: Mild/moderate TEAEs; 0 drug-related SAEs │
└──────────────────────────────┬──────────────────────────────┘
│
▼
┌─────────────────────────────────────────────────────────────┐
│ 32-Week Open-Label Extension (Ongoing Durability) │
└─────────────────────────────────────────────────────────────┘
The clinical findings reported on August 18, 2026, confirmed efficacy across every hierarchically tested endpoint:
| Endpoint Hierarchy | Definition / Clinical Measure | Trial Finding (16-Week DB) | Statistical Significance | Clinical & Payer Relevance |
|---|---|---|---|---|
| Primary Endpoint | Composite rate of Level 2 (<54 mg/dL) and Level 3 (severe neuroglycopenia requiring third-party assistance) events | 55% rate reduction vs placebo | p = 0.000003 | Met the FDA-agreed registrational endpoint; effect size consistent with the phase 2 program |
| Secondary Endpoint 1 | Self-Monitored Blood Glucose (SMBG) Level 2 event rate | Statistically significant reduction | "Highly statistically significant" per release | Confirms patient-verified point-of-care clinical benefit |
| Secondary Endpoint 2 | Continuous Glucose Monitoring (CGM) sensor glucose < 54 mg/dL event rate | Statistically significant reduction | "Highly statistically significant" per release | Demonstrates continuous, objective interstitial glycemic protection |
| Secondary Endpoint 3 | Independently adjudicated Level 3 severe hypoglycemic events | Statistically significant reduction | "Highly statistically significant" per release | Directly addresses acute emergency room (ER), EMS, and hospitalization risk |
| Weight Trajectory | Change in body weight from baseline at Week 16 | No difference vs placebo | Non-significant | Eliminates the primary theoretical risk that blocking GLP-1 would trigger severe weight regain in post-bariatric patients |
| Safety & Tolerability | Treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) | Mild to moderate TEAEs; 0 drug-related SAEs | N/A | Favorable risk-benefit profile for chronic outpatient self-administration |
The clinical significance of the primary endpoint cannot be overstated. In severe PBH, patients experience profound postprandial glucose nadirs, frequently dropping below 54 mg/dL 1 to 3 hours after carbohydrate ingestion. Level 3 events cause severe neuroglycopenic symptoms, including confusion, loss of consciousness, diaphoresis, grand mal seizures, cognitive impairment, and automobile accidents.
For a broader perspective on how clinical trial endpoints translate into market-access decisions in metabolic disease, see our analysis of retatrutide TRIUMPH-1 phase 3 evidence.
What is post-bariatric hypoglycemia and what is the patient population?
Post-bariatric hypoglycemia is an underdiagnosed, debilitating late complication of metabolic and bariatric surgery. While initially described almost exclusively in patients following Roux-en-Y gastric bypass (RYGB), PBH is increasingly diagnosed following sleeve gastrectomy (SG).
┌─────────────────────────────────────────────────────────────┐
│ PATHOPHYSIOLOGY OF POST-BARIATRIC HYPOGLYCEMIA │
└──────────────────────────────┬──────────────────────────────┘
│
┌────────────────────────────────────────────┴────────────────────────────────────────────┐
│ │
▼ ▼
┌──────────────────────────────────────────────┐ ┌──────────────────────────────────────────────┐
│ Altered Anatomy & Motility │ │ Exaggerated Incretin Surge │
├──────────────────────────────────────────────┤ ├──────────────────────────────────────────────┤
│ • Surgical bypass of pyloric sphincter │ │ • Rapid glucose delivery to distal L-cells │
│ • Rapid, unregulated nutrient transit into │ │ • Postprandial GLP-1 secretion surges up to │
│ the distal Roux limb and jejunum │ │ 10x to 20x above normal physiological levels│
└──────────────────────┬───────────────────────┘ └──────────────────────┬───────────────────────┘
│ │
└──────────────────────────────┬──────────────────────────────────────────┘
│
▼
┌──────────────────────────────────────────────┐
│ Pathological Hyperinsulinemic Surge │
│ Excess GLP-1 binds beta-cell receptors; │
│ triggers massive insulin secretion despite │
│ falling systemic arterial glucose │
└──────────────────────┬───────────────────────┘
│
▼
┌──────────────────────────────────────────────┐
│ Severe Postprandial Neuroglycopenia │
│ Blood glucose plunges <54 mg/dL (Level 2); │
│ Seizures, syncope, cognitive crashes (Lev 3)│
└──────────────────────────────────────────────┘
The underlying mechanism represents an ironic biological inversion:
- Anatomical Acceleration: Bariatric surgery alters gastrointestinal transit. Rapid gastric emptying delivers concentrated carbohydrate chyme directly into the distal intestine without normal pyloric regulation.
- Incretin Hypersecretion: Nutrient contact with distal intestinal L-cells stimulates an exaggerated release of native GLP-1, producing circulating postprandial GLP-1 concentrations 10 to 20 times higher than in unoperated individuals.
- Beta-Cell Hyperactivation: This massive surge of endogenous GLP-1 overstimulates pancreatic beta-cell GLP-1 receptors, driving excessive, unregulated insulin secretion (hyperinsulinemic hypoglycemia).
- Neuroglycopenic Crash: Unlike reactive hypoglycemia, where glucose stabilizes, PBH patients experience precipitous glucose crashes that trigger neuroglycopenic crises within 60 to 180 minutes of eating.
Clinical Diagnosis and Mixed-Meal Testing Criteria
Establishing a definitive clinical diagnosis of PBH requires distinguishing postprandial hyperinsulinism from dumping syndrome and insulinoma:
- Whipple's Triad: Documentation of hypoglycemic symptoms, concomitant plasma glucose < 54 mg/dL, and immediate symptom resolution following glucose ingestion.
- Mixed-Meal Tolerance Testing (MMTT): A standardized liquid mixed meal (e.g., 200–300 kcal with balanced carbohydrate, protein, and fat) is administered following an overnight fast. Blood samples drawn every 30 minutes for 180 minutes capture the characteristic initial glucose spike followed by rapid hyperinsulinemic decline to <54 mg/dL.
- Continuous Glucose Monitoring (CGM) Patterns: Demonstrates postprandial hypoglycemia recurring predominantly within 1 to 4 hours of meals, with preserved fasting normoglycemia (ruling out insulinoma).
Epidemiology and Target Population
Clinically significant PBH develops in a minority of patients who undergo Roux-en-Y gastric bypass or sleeve gastrectomy. Amylyx's trial announcement cites a prevalence of approximately 8% of people in the U.S. who have undergone the two most common bariatric procedures, for a prevalent population the company estimates at approximately 160,000 individuals; the peer-reviewed clinical literature (Salehi et al., JCEM 2018) characterizes the syndrome and its diagnosis but does not independently re-derive that population figure.
The estimate sits in a unique commercial and reimbursement niche: substantially larger than typical ultra-rare monogenic diseases (e.g., GSD1a or congenital hyperinsulinism), yet defined enough to have qualified avexitide for Orphan Drug Designation under the Orphan Drug Act (statutory threshold of <200,000 U.S. patients).
What payers cover today: the off-label stepped pathway and NADAC pricing
Prior to avexitide’s Phase 3 success, no pharmaceutical agent had ever earned FDA approval for PBH. Managed care organizations and Medicaid programs have managed PBH through an unstandardized, stepped sequence of dietary modification followed by off-label generic pharmacotherapy.
To benchmark the existing baseline spend, we audited unit pricing from the CMS National Average Drug Acquisition Cost (NADAC) dataset (snapshot 2026-07-24) across the three primary off-label generic pillars:
| Stepped Care Level | Therapeutic Agent | Mechanism of Action in PBH | NADAC Unit Price (2026-07-24 Snapshot) | Clinical Limitations & Tolerability Failure Modes |
|---|---|---|---|---|
| Step 1: Dietary | Medical Nutrition Therapy | Strict restriction of high-glycemic carbohydrates; frequent small meals high in protein/fiber | Minimal direct pharmacy cost; high patient compliance burden | Fails in moderate-to-severe disease; patients experience neuroglycopenia even on strict complex carbohydrate regimens |
| Step 2: Oral | Acarbose (Tablets: 25 mg, 50 mg, 100 mg) | Alpha-glucosidase inhibitor; delays carbohydrate digestion in the small intestine | $0.15747 – $0.23161 per tablet across generic tablet presentations (100 mg presentation: $0.23161) | Severe gastrointestinal adverse effects (flatulence, abdominal cramping, diarrhea) drive frequent treatment discontinuation; minimal efficacy in severe PBH |
| Step 3: SubQ | Octreotide Acetate (Generic Injection Vials) | Somatostatin analogue; inhibits insulin, glucagon, and gastrointestinal hormone release | $2.53907 – $5.34040 per mL across generic vial concentrations (100 mcg per mL vial: $2.53907/mL; 1000 mcg per 5 mL vial: $5.34040/mL) | Short half-life requires painful TID subcutaneous injections; suppresses counter-regulatory glucagon, risking severe rebound hypoglycemia; biliary sludge and gallstones with chronic use |
| Step 4: Oral | Diazoxide (Oral Suspension 50 mg/mL) | Opens ATP-sensitive potassium channels in beta cells, inhibiting insulin exocytosis | $7.01097 per mL (Oral suspension: $7.01097/mL) | Fluid retention, peripheral edema, congestive heart failure exacerbation, hypertrichosis (abnormal hair growth), nausea, and hyperuricemia |
| Step 5: Surgical | Surgical Reversal / Pancreatectomy | Anatomical conversion back to normal anatomy or partial/total resection of the pancreas | $30,000 – $75,000+ per surgical hospitalization (inpatient medical benefit) | High surgical morbidity; pancreatectomy trades hypoglycemia for brittle insulin-dependent diabetes; does not guarantee symptom resolution |
┌─────────────────────────────────────────────────────────────┐
│ EXISTING OFF-LABEL STEPPED CARE PARADOX │
└──────────────────────────────┬──────────────────────────────┘
│
┌────────────────────────────────────────────┼────────────────────────────────────────────┐
│ │ │
▼ ▼ ▼
┌──────────────────┐ ┌──────────────────┐ ┌──────────────────┐
│ Acarbose │ │ Octreotide │ │ Diazoxide │
│ $0.23 / tablet │ │ $2.54 - $5.34/mL│ │ $7.01 / mL │
├──────────────────┤ ├──────────────────┤ ├──────────────────┤
│ Severe GI distress│ │ TID injections; │ │ Fluid retention; │
│ frequent discont. │ │ rebound hypoglyc.│ │ hypertrichosis │
└──────────────────┘ └──────────────────┘ └──────────────────┘
The data reveals the central economic and clinical paradox facing payers: while the existing off-label drugs are chemically commoditized with negligible acquisition costs, their clinical utility is severely capped by side effects and paradoxical counter-regulatory blunting.
Two measurement caveats apply to these NADAC figures. First, they are unit prices only; regimen costs are not derived because off-label PBH dosing varies and is not label-defined. Second, the generic injection rows above cover short-acting octreotide vials only—long-acting depot formulations, a common chronic form, do not appear in these generic rows, so the table understates real-world octreotide spend.
In-Depth Failure Modes of Current Pharmacotherapies
- Acarbose (Alpha-Glucosidase Inhibition): Acarbose acts locally in the brush border of the small intestine to inhibit alpha-glucosidase enzymes, delaying carbohydrate breakdown. However, because bariatric surgery alters proximal intestinal transit, unabsorbed carbohydrates reach the colon rapidly, producing bacterial fermentation. Many bariatric patients cannot tolerate the resulting bloating, abdominal pain, and diarrhea, and discontinue the drug.
- Octreotide (Somatostatin Receptor Agonism): Octreotide binds somatostatin receptors (predominantly sst2 and sst5) on pancreatic islet cells, suppressing both insulin and glucagon secretion. While octreotide blunts postprandial insulin surges, its simultaneous inhibition of glucagon strips patients of their primary physiological defense against falling glucose, and patients can experience severe nocturnal or delayed rebound hypoglycemia. Chronic octreotide therapy also alters biliary motility, and biliary sludge and gallstones are well-documented complications of long-term use.
- Diazoxide (K-ATP Channel Opening): Diazoxide prevents beta-cell depolarization by keeping ATP-sensitive potassium channels open, reducing insulin exocytosis. However, diazoxide induces severe renal sodium and water retention, frequently leading to peripheral edema, hypertension, and exacerbation of heart failure. Its cosmetic side effects, particularly generalized hypertrichosis, lead to high discontinuation among female patients.
When patients fail acarbose, octreotide, and diazoxide, their access pathway dead-ends into repetitive emergency department visits, continuous glucose monitor denials, or high-cost surgical revisions.
For context on how orphan drugs transition from unapproved off-label management into formal specialty tiering, see our analysis of DTX401 GSD1a gene therapy payer ask and olezarsen Tryngolza launch pricing.
Why a GLP-1 antagonist: mechanism and trial lineage from PREVENT to LUCIDITY
Avexitide (formerly designated as exendin 9-39) is a first-in-class 31-amino-acid peptide that functions as a selective, competitive antagonist of the GLP-1 receptor.
By binding to the GLP-1 receptor on pancreatic beta cells without activating intracellular cyclic AMP (cAMP) signaling, avexitide competitively displaces endogenous GLP-1. This normalizes postprandial insulin secretion to match actual systemic glucose levels rather than the exaggerated incretin signal.
┌─────────────────────────────────────────────────────────────┐
│ AVEXITIDE CLINICAL DEVELOPMENT LINEAGE │
└──────────────────────────────┬──────────────────────────────┘
│
▼
┌─────────────────────────────────────────────────────────────┐
│ PREVENT Trial (Academic Phase 2 Proof-of-Concept) │
│ Randomized, Placebo-Controlled Crossover │
├─────────────────────────────────────────────────────────────┤
│ • Demonstrated exendin 9-39 blunts postprandial insulin surge│
│ • Prevented nadir hypoglycemia during oral glucose challenge│
│ • Published in peer-reviewed literature (PMC8277203) │
└──────────────────────────────┬──────────────────────────────┘
│
▼
┌─────────────────────────────────────────────────────────────┐
│ Phase 2b Trial (NCT04652479 / ENDO 2022 Data) │
│ 16 Patients; 45 mg BID or 90 mg QD for 28 Days │
├─────────────────────────────────────────────────────────────┤
│ • 53% to 68% reduction in Level 1-3 hypoglycemia event rates│
│ • Established 90 mg once-daily SubQ as optimal regimen │
│ • Showed sustained symptom relief over 28-day outpatient use│
└──────────────────────────────┬──────────────────────────────┘
│
▼
┌─────────────────────────────────────────────────────────────┐
│ Phase 3 LUCIDITY Pivotal Trial (NCT06747468) │
│ 78 Patients; 90 mg QD SubQ vs Placebo (16 Wk DB) │
├─────────────────────────────────────────────────────────────┤
│ • 55% reduction in composite Level 2/3 events (p=0.000003) │
│ • Met all secondary endpoints (SMBG, CGM, Level 3 events) │
│ • Weight neutral; zero drug-related SAEs; NDA late 2026 │
└─────────────────────────────────────────────────────────────┘
The clinical evidence supporting avexitide rests on a seamless, decade-long development lineage:
- PREVENT Trial (Phase 2 Academic Foundation; PMC8277203): Conducted at Stanford University and academic medical centers, this randomized, double-blind, placebo-controlled crossover study established that continuous intravenous infusion and subcutaneous administration of avexitide significantly elevated postprandial glucose nadirs and reduced insulin hypersecretion following oral glucose tolerance testing.
- Phase 2b Dose-Ranging Trial (NCT04652479; Eiger BioPharmaceuticals): Presented at ENDO 2022, this 28-day outpatient study in 16 participants evaluated 45 mg twice daily versus 90 mg once daily. Avexitide achieved a 53% to 68% reduction across Level 1, 2, and 3 hypoglycemic events, confirming that 90 mg once daily provided equivalent 24-hour pharmacokinetic coverage with superior patient convenience.
- Phase 3 LUCIDITY Trial (NCT06747468; Amylyx): Expanded the cohort to 78 participants across 21 centers, confirming that the 55% reduction in severe events observed in Phase 2b is fully reproducible in a powered, registrational double-blind trial.
Regulatory designations, transaction history, and competitive pipeline
Avexitide's regulatory pedigree reflects substantial FDA engagement across multiple rare endocrine indications:
┌─────────────────────────────────────────────────────────────┐
│ AVEXITIDE REGULATORY DESIGNATION INVENTORY │
└──────────────────────────────┬──────────────────────────────┘
│
┌────────────────────────────────────────────┼────────────────────────────────────────────┐
│ │ │
▼ ▼ ▼
┌──────────────────┐ ┌──────────────────┐ ┌──────────────────┐
│ Breakthrough │ │ Orphan Drug │ │ Rare Pediatric │
│ Designation │ │ Designation │ │ Disease │
├──────────────────┤ ├──────────────────┤ ├──────────────────┤
│ Granted for PBH │ │ Covers all Hyper-│ │ Granted for │
│ and Congenital HI│ │ insulinemic Hypo.│ │ Congenital HI │
└──────────────────┘ └──────────────────┘ └──────────────────┘
The $35.1 Million Eiger Asset Purchase
Amylyx acquired avexitide on July 9, 2024, through a Chapter 11 Section 363 asset purchase agreement from bankrupt Eiger BioPharmaceuticals. Amylyx paid $35.1 million in cash, plus assumed liabilities and determined cure costs, and agreed to a 3% net sales royalty payable to certain academic institutions on future PBH revenues.
Amylyx Corporate Context: The Post-Relyvrio Rebuild
For healthcare payers and Wall Street analysts, avexitide represents Amylyx's critical pipeline pivot.
In 2022, Amylyx won FDA approval for Relyvrio (sodium phenylbutyrate/taurursodiol) in amyotrophic lateral sclerosis (ALS) on the strength of a small phase 2 dataset. However, in April 2024, following the failure of the confirmatory Phase 3 PHOENIX trial, Amylyx voluntarily withdrew Relyvrio from the market.
According to Amylyx's Q2 2026 financial report (August 6, 2026), the company maintains cash runway into 2028. Unlike Relyvrio's disputed Phase 2 dataset, avexitide’s Phase 3 LUCIDITY trial met its primary endpoint with an unquestionable p-value (p = 0.000003), providing strong regulatory validation ahead of the planned late-2026 NDA submission.
Competitive Pipeline in Post-Bariatric Hypoglycemia
While avexitide is the only candidate to complete Phase 3 testing, two competing assets are in active development:
| Drug Candidate | Sponsor | Modality & Mechanism | Development Phase & Timeline | Route of Admin & Target Profile |
|---|---|---|---|---|
| Avexitide | Amylyx Pharmaceuticals | GLP-1 Receptor Antagonist (31-amino-acid peptide) | Phase 3 Completed (LUCIDITY); NDA filing planned by end of 2026 | 90 mg once-daily SubQ injection; 55% event reduction; weight neutral |
| Pasireotide | Recordati Rare Diseases | Somatostatin Analogue (sst1, sst2, sst3, sst5 multi-receptor agonist) | Phase 2 completed positive; Phase 3 program to be finalized by end of 2026 | Subcutaneous injection; broader hormone suppression; risks hyperglycemia |
| Mizagliflozin | Vogenx | Oral SGLT1 Inhibitor (gastrointestinal sodium-glucose co-transporter blocker) | Phase 2a completed; entering Phase 2b clinical testing | Oral tablet taken prior to meals; delays gut glucose absorption; non-peptide |
How payers should structure the avexitide prior authorization policy
When avexitide receives FDA approval in 2027, specialty pharmacy directors will face immediate prior authorization requests from endocrinologists and bariatric surgeons.
Because avexitide will launch as a branded orphan biologic with daily subcutaneous administration, payers must establish evidence-based PA criteria that ensure access for severe patients while preventing off-label drift.
┌─────────────────────────────────────────────────────────────┐
│ RECOMMENDED AVEXITIDE PRIOR AUTHORIZATION CRITERIA │
└──────────────────────────────┬──────────────────────────────┘
│
┌────────────────────────────────────────────┼────────────────────────────────────────────┐
│ │ │
▼ ▼ ▼
┌──────────────────┐ ┌──────────────────┐ ┌──────────────────┐
│ Step 1: Surgical │ │ Step 2: Glycemic │ │ Step 3: Prior Tx │
│ Documentation │ │ Validation │ │ Step Therapy │
├──────────────────┤ ├──────────────────┤ ├──────────────────┤
│ • History of RYGB│ │ • Documented │ │ • Documented │
│ or sleeve gast.│ │ Level 2/3 PBH │ │ failure of MNT │
│ • Surgery >= 6 mo│ │ • CGM / SMBG logs│ │ • Trial/failure │
│ prior to claim │ │ or MMTT nadir │ │ of acarbose │
└──────────────────┘ └──────────────────┘ └──────────────────┘
A robust, defensible Prior Authorization (PA) skeleton should incorporate three mandatory clinical gates:
Gate 1: Anatomical and Surgical Qualification
- Patient is ≥18 years of age.
- Documented history of Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy performed at least 6 months prior to initiation (ICD-10 Z98.84, K91.89).
- Exclusion of alternative causes of hypoglycemia (e.g., insulinoma, surreptitious insulin administration, primary adrenal insufficiency, or severe renal failure).
Gate 2: Objective Glycemic and Clinical Severity Documentation
- Documentation of recurrent postprandial hypoglycemia occurring within 1 to 4 hours of meals.
- Documented Level 2 hypoglycemia (interstitial or capillary blood glucose < 54 mg/dL) verified via Continuous Glucose Monitoring (CGM) or Self-Monitored Blood Glucose (SMBG) logs over at least 14 days, OR
- Documented severe Level 3 neuroglycopenic event requiring third-party assistance within the preceding 6 months, OR
- Diagnostic confirmation via a standardized Mixed-Meal Tolerance Test (MMTT; CPT 82951, 82952) demonstrating a postprandial nadir < 54 mg/dL with concurrent neuroglycopenic symptoms (Whipple's triad).
Gate 3: Stepped Pharmacotherapy and Nutrition Failure
- Documented failure or inability to control symptoms with Medical Nutrition Therapy (low-glycemic-index, high-protein, carbohydrate-controlled diet) supervised by a registered dietitian or endocrinologist.
- Documented trial (minimum 30 days) and failure, contraindication, or intolerable adverse reaction to generic acarbose.
- (Optional Payer Step): Documented trial and failure or contraindication to generic subcutaneous octreotide or diazoxide.
Reauthorization Criteria (Annual Renewal)
- Objective reduction in monthly Level 2 and Level 3 hypoglycemic events from baseline verified by CGM/SMBG download.
- Absence of severe treatment-limiting adverse events.
- Continued maintenance of post-bariatric weight loss goals (confirming lack of paradoxical weight gain).
For comparative payer policy frameworks on how plans manage bariatric surgery patients on incretin-pathway drugs, see our analysis of Aetna GLP-1 coverage criteria bariatric surgery.
Frequently Asked Questions
Is there an FDA-approved drug for post-bariatric hypoglycemia today?
No. There are currently zero FDA-approved pharmacotherapies for post-bariatric hypoglycemia. All medical management relies on dietary modification and off-label generic drugs such as acarbose, octreotide, and diazoxide. Avexitide is poised to become the first approved therapy following its late-2026 NDA submission.
When will avexitide be submitted to the FDA and potentially approved?
Amylyx has announced plans to submit an NDA to the FDA by the end of 2026. Breakthrough Therapy Designation makes the company eligible to request Priority Review (a 6-month review cycle) if it chooses; Amylyx has said it is preparing for a potential commercial launch in 2027, if approved.
Does avexitide cause weight regain in bariatric patients?
No. In the 16-week double-blind portion of the Phase 3 LUCIDITY trial, there was no statistically significant difference in body weight between participants receiving avexitide and those receiving placebo. This confirmed that blocking pancreatic GLP-1 receptors in PBH patients does not reverse surgical weight loss.
How much do the off-label generic alternatives cost per unit?
According to CMS NADAC data (snapshot 2026-07-24), generic acarbose costs $0.15747 to $0.23161 per tablet; generic octreotide acetate injection costs $2.53907 to $5.34040 per mL; and generic diazoxide oral suspension costs $7.01097 per mL. However, their high gastrointestinal and cardiovascular side-effect rates result in frequent treatment discontinuation.
How can eligible patients access avexitide before FDA approval?
Amylyx operates a U.S. Expanded Access Program (EAP), launched in May 2026 and ongoing per the company's August 18, 2026 announcement, for adults with post-bariatric hypoglycemia who meet the program's eligibility criteria. Treating physicians can apply through Amylyx Medical Affairs.
Sources
- Amylyx Pharmaceuticals, Inc. Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia. Corporate Press Release via Business Wire, August 18, 2026.
https://www.amylyx.com/news/amylyx-pharmaceuticals-announces-positive-topline-results-from-phase-3-lucidity-clinical-trial-of-avexitide-in-post-bariatric-hypoglycemia - ClinicalTrials.gov. A Study to Evaluate the Efficacy and Safety of Avexitide in Participants With Post-Bariatric Hypoglycemia (LUCIDITY). Identifier: NCT06747468. Sponsor: Amylyx Pharmaceuticals.
https://clinicaltrials.gov/study/NCT06747468 - PubMed Central (PMC). PREVENT: A Randomized, Placebo-Controlled Crossover Trial of Avexitide (Exendin 9-39) in Post-Bariatric Hypoglycemia. PMC8277203, 2021.
https://pmc.ncbi.nlm.nih.gov/articles/PMC8277203/ - Amylyx Pharmaceuticals, Inc. Amylyx Pharmaceuticals Announces Acquisition of Phase 3-Ready GLP-1 Receptor Antagonist Avexitide With FDA Breakthrough Therapy Designation. Press Release, July 9, 2024.
https://www.amylyx.com/news/amylyx-pharmaceuticals-announces-acquisition-of-phase-3-ready-glp-1-receptor-antagonist-avexitide-with-fda-breakthrough-therapy-designation - Eiger BioPharmaceuticals, Inc. Eiger BioPharmaceuticals Announces New Data Supporting Broader Potential of Avexitide in Patients with Post-Bariatric Hypoglycemia and Hyperinsulinemic Hypoglycemia (ENDO 2022). PR Newswire, June 13, 2022.
https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-announces-new-data-supporting-broader-potential-of-avexitide-in-patients-with-post-bariatric-hypoglycemia-and-hyperinsulinemic-hypoglycemia-after-gastrointestinal-surgeries-301566413.html - Centers for Medicare & Medicaid Services (CMS). National Average Drug Acquisition Cost (NADAC) Database. (Relational snapshot 2026-07-24; records for acarbose, octreotide acetate, and diazoxide).
https://data.medicaid.gov/dataset/4f4a1c1a-65b1-4cf8-9156-3725662f1d5d - The Journal of Clinical Endocrinology & Metabolism (JCEM). Salehi, M., Vella, A., McLaughlin, T., & Patti, M.E. Hypoglycemia After Gastric Bypass Surgery: Current Concepts and Controversies. J Clin Endocrinol Metab, 2018;103(8):2815-2826.
https://pmc.ncbi.nlm.nih.gov/articles/PMC6692713/ - FDA Office of Orphan Products Development (OOPD). Orphan Drug Designations and Approvals Database: search for Avexitide / Exendin (9-39) hyperinsulinemic hypoglycemia designations.
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/ - Amylyx Pharmaceuticals, Inc. Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric Hypoglycemia. Corporate Press Release, 2026.
https://www.amylyx.com/news/amylyx-pharmaceuticals-announces-us-expanded-access-program-for-adults-with-post-bariatric-hypoglycemia
